• COVID-19
  • Allergies and Infant Formula
  • Pharmacology
  • Telemedicine
  • Drug Pipeline News
  • Influenza
  • Allergy, Immunology, and ENT
  • Autism
  • Cardiology
  • Emergency Medicine
  • Endocrinology
  • Adolescent Medicine
  • Gastroenterology
  • Infectious disease
  • Nutrition
  • Neurology
  • Obstetrics-Gynecology & Women's Health
  • Developmental/Behavioral Disorders
  • Practice Improvement
  • Gynecology
  • Respiratory
  • Dermatology
  • Diabetes
  • Mental Health
  • Oncology
  • Psychiatry
  • Animal Allergies
  • Alcohol Abuse
  • Rheumatoid Arthritis
  • Sexual Health
  • Pain

Flu vaccine additive targets more than 1 virus

Article

Novartis has introduced a vaccine additive that is designed to enhance immune response to various viruses.

Novartis has introduced a vaccine additive that is designed to enhance immune response to various viruses. The adjuvant, dubbed MF59 and already available as part of influenza shots used in Europe, targets the H5N1 virus in the experimental bird flu vaccine, as well as mutant viruses, according to a new FDA study published in the January 20, 2010, issue of Science Translational Medicine.

"MF59 adjuvant improves the immune response to a H5N1 vaccine by inducing qualitative and quantitative expansion of the antibody repertoires with protective potential," reported the FDA research team led by Hana Golding, PhD, FDA scientist.

Adjuvants are intended to expand the body's ability to react to a vaccine, reducing the amount of antigen necessary. To date, adjuvants, although broadly used in flu vaccines in Europe, are not commonly used in the United States despite the fact that the federal government has spent close to $700 million purchasing them.

Related Videos
Donna Hallas, PhD, CPNP, PPCNP-BC, PMHS, FAANP, FAAN
Scott Ceresnak, MD
Scott Ceresnak, MD
Importance of maternal influenza vaccination recommendations
Reducing HIV reservoirs in neonates with very early antiretroviral therapy | Deborah Persaud, MD
Samantha Olson, MPH
Deborah Persaud, MD
Ari Brown, MD, FAAP | Pediatrician and CEO of 411 Pediatrics; author, baby411 book series; chief medical advisor, Kabrita USA.
© 2024 MJH Life Sciences

All rights reserved.